Vaccination of TLR7/8 Agonist‐Conjugated Antigen Nanoparticles for Cancer Immunotherapy

Abstract

AbstractNanovaccine‐based immunotherapy can initiate strong immune responses and establish a long‐term immune memory to prevent tumor invasion and recurrence. Herein, the assembly of redox‐responsive antigen nanoparticles (NPs) conjugated with imidazoquinoline‐based TLR7/8 agonists for lymph node‐targeted immune activation is reported, which can potentiate tumor therapy and prevention. Antigen NPs are assembled via the templating of zeolitic imidazolate framework‐8 NPs to cross‐link ovalbumin with disulfide bonds, which enables the NPs with redox‐responsiveness for improved antigen cross‐presentation and dendritic cell activation. The formulated nanovaccines promote the lymphatic co‐delivery of antigens and agonists, which can trigger immune responses of cytotoxic T lymphocytes and strong immunological memory. Notably, nanovaccines demonstrate their superiority for tumor prevention owing to the elicited robust antitumor immunity. The reported strategy provides a rational design of nanovaccines for enhanced cancer immunotherapy.